Blackrock Neurotech in a $10 million financing round led by Christian Angermayer's re.Mind Capital.

Blackrock Neurotech, a German startup operated from Salt Lake City (USA) and building a platform for brain-computer interface (BCI) technology and manufacturing, announced the completion of a $10 million capital funding round.

The money was raised from investors led by Christian Angermayer's re.Mind Capital (Apeiron Investment Group) with participation from Peter Thiel, German entrepreneur Tim Sievers, and Sorenson Impact's University Venture Fund II.

Christian Angermayer and Jan Hardorp of re.Mind, as well as Tim Sievers will join the Blackrock Neurotech Board of Directors.

The funding will be used to further expand the number of programs on the Blackrock platform – including clinical studies and cutting-edge research – and to continue development of its technology platform to maintain a leading position in the market.

In addition to the investment announcement, Blackrock today will begin using the brand Blackrock Neurotech to better reflect the company's longstanding focus on neurotechnology and BCI. The company will keep the Blackrock Microsystems brand in place for continuity with its thriving research community.

Blackrock Neurotech, founded in 2015 by Florian Solzbacher and CEO Marcus Gerhardt, builds clinical translation and brain-computer interface (BCI) technology. The founders have been working on the core tech since 2008 - a precision electrode technology - that powers the Brain-Computer Interfaces (BCI) and through neural signal processing and stimulation has enabled BCI Pioneers to walk, talk, see, hear, and feel.

Blackrock Neurotech has powered a wide range of "firsts" in human BCI applications: for example, the first to provide tetraplegic patients the ability to control robotic limbs directly from and with the brain; and the first to enable ALS patients, even completely locked-in ones, to communicate again via an auditory speller, directly controlled by their mind.